BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

BioAge Labs said it is preparing Phase 2 readouts for BGE-102, an oral NLRP3 inflammasome inhibitor, aimed at heart risk and diabetic eye disease. The trial will test 30/60/90 mg once daily for 3 months to support dose selection and expand safety data. BioAge reported about $385 million cash at Q1 end and is planning an ASCVD outcomes (MACE) strategy.

BioAge (Nasdaq: BIOA) will host an R&D Day webcast on May 8, 2026, to present Phase 1 clinical data for its orally available NLRP3 inflammasome inhibitor, BGE-102. The event will focus on the therapeutic rationale for BGE-102 in atherosclerotic cardiovascular disease (ASCVD) and retinal disease, with four academic and clinical experts joining BioAge management for presentations and a Q&A session. This follows previous positive Phase 1 data for BGE-102, which showed reductions in inflammatory biomarkers.

BioAge Labs, Inc. announced it will host an R&D Day webcast on May 8, 2026, to discuss its lead product candidate, BGE-102, an NLRP3 inflammasome inhibitor. The event will feature Phase 1 clinical data for BGE-102 and its therapeutic rationale for atherosclerotic cardiovascular disease and retinal disease. Experts in relevant fields will join BioAge management to provide insights on NLRP3 biology and the target diseases.

A Form 144 filing indicates that Paul Rubin reported three separate sales of 7,433 shares each of BIOA stock on January 2, 2026, February 2, 2026, and March 2, 2026, receiving proceeds of $95,490.42, $139,368.75, and $148,882.99, respectively. The filing also lists future sales of 5,437 shares and 3,383 shares to be sold on April 1, 2026, related to options granted in 2020 and 2022. Fidelity Brokerage Services LLC is referenced as the broker for these transactions.

Fenwick represented BioAge Labs, Inc. in its upsized underwritten public offering, which raised approximately $115.0 million. The biopharmaceutical company offered 5,897,435 shares of its common stock at $19.50 per share, with an option for underwriters to purchase additional shares. Goldman Sachs & Co. LLC, Piper Sandler, and Citigroup served as joint book-running managers.

BioAge Labs has entered into an underwriting agreement with Goldman Sachs, Piper Sandler, and Citigroup Global Markets to sell 5,897,435 shares of common stock at $19.50 per share, with an option for underwriters to purchase additional shares. The company anticipates raising approximately $107.6 million in net proceeds, which will fund research, clinical, and manufacturing efforts, including programs for BGE-102, NLRP3, and APJ, as well as general corporate purposes. The transaction is expected to close on January 23, 2026.